BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33592139)

  • 1. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
    Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
    Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.
    Bobbili P; Ryan K; Duh MS; Dua A; Fernandes AW; Pavilack M; Gomez JE
    Future Oncol; 2019 Oct; 15(29):3381-3393. PubMed ID: 31544510
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
    Martinez-Meehan D; Lutfi W; Dhupar R; Christie N; Baker N; Schuchert M; Luketich JD; Okusanya OT
    Clin Lung Cancer; 2020 Jul; 21(4):349-356. PubMed ID: 32299769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?
    Collaud S; Provost B; Besse B; Fabre D; Le Chevalier T; Mercier O; Mussot S; Fadel E
    J Surg Oncol; 2018 Jun; 117(7):1570-1574. PubMed ID: 29573419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
    Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
    Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.
    Grosu HB; Manzanera A; Shivakumar S; Sun S; Noguras Gonzalez G; Ost DE
    Lung Cancer; 2020 Feb; 140():55-58. PubMed ID: 31865279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
    Hansen RN; Zhang Y; Seal B; Ryan K; Yong C; Darilay A; Ramsey SD
    BMC Cancer; 2020 Apr; 20(1):276. PubMed ID: 32248816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
    She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W
    Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer.
    Kumar A; Srinivasan D; Potter AL; Mathey-Andrews C; Lanuti M; Martin LW; Jeffrey Yang CF
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1895-1905.e2. PubMed ID: 37722622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
    Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
    Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage III Non-small Cell Lung Cancer Management in England.
    Adizie JB; Khakwani A; Beckett P; Navani N; West D; Woolhouse I; Harden SV
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):688-696. PubMed ID: 31514942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
    Phernambucq EC; Hartemink KJ; Smit EF; Paul MA; Postmus PE; Comans EF; Senan S
    J Thorac Oncol; 2012 Aug; 7(8):1271-5. PubMed ID: 22659960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.